איקלוסיג 15 מג
medison pharma ltd - ponatinib as hydrochloride - טבליות מצופות - ponatinib as hydrochloride 15 mg - ponatinib
איקלוסיג 15 מג
medison pharma ltd - ponatinib as hydrochloride - טבליות מצופות - ponatinib as hydrochloride 15 mg - ponatinib
איקלוסיג 15 מג
medison pharma ltd - ponatinib as hydrochloride - טבליות מצופות - ponatinib as hydrochloride 15 mg - ponatinib
איקלוסיג 30 מג
medison pharma ltd - ponatinib as hydrochloride - טבליות מצופות - ponatinib as hydrochloride 30 mg - ponatinib
איקלוסיג 30 מג
medison pharma ltd - ponatinib as hydrochloride - טבליות מצופות - ponatinib as hydrochloride 30 mg - ponatinib
איקלוסיג 45 מג
medison pharma ltd - ponatinib as hydrochloride - טבליות מצופות - ponatinib as hydrochloride 45 mg - ponatinib
איקלוסיג 45 מג
medison pharma ltd - ponatinib as hydrochloride - טבליות מצופות - ponatinib as hydrochloride 45 mg - ponatinib
טייסברי
medison pharma ltd - natalizumab - תרכיז להכנת תמיסה לאינפוזיה - natalizumab 300 mg / 15 ml - natalizumab - natalizumab - tysabri is indicated as monotherapy for the treatment of patients with relapsing forms of multiple sclerosis . to delay the accumulation of physical disability and reduce the frequency of clinical exacerbations. the safety and efficacy of tysabri beyond two years are unknown. because tysabri increases the risk of progressive multifocal leukoencephalopathy (pml), an opportunistic viral infection of the brain that usually leads to death or severe disability. tysabri is generally recommended for patients who have had an inadequate response to, or are unable to tolerate, alternate multiple sclerosis therapies. safety and efficacy in patients with chronic progressive multiple sclerosis have not been studied.
פקפנט 100
medison pharma ltd - fentanyl as citrate - ספריי לאף - fentanyl as citrate 1 mg / 1 ml - fentanyl
פקפנט 400
medison pharma ltd - fentanyl as citrate - ספריי לאף - fentanyl as citrate 4 mg / 1 ml - fentanyl